Eficacia del CA 15.3, en el seguimiento del tratamiento y evolución, en pacientes de 35-75 años con cáncer de mama en el HETMC, junio 2018 - junio 2019.

Abstract

Introduction: The high CA15-3 marker titles show the poor response to treatment in locally advanced disease and it is found elevated in most patients with metastatic breast cancer. Objectives: To demonstrate the usefulness of the tumor marker CA 15-3 in monitoring the treatment and evolution of patients aged 35 to 75 years with a diagnosis of breast cancer who attend the Teodoro Maldonado Carbo Specialty Hospital. Methodology: The present study has an observational, retrospective, analytical, longitudinal design. The population was made up of patients who come to the outpatient clinic of the Teodoro Maldonado Carbo Specialty Hospital in the city of Guayaquil, in the period from June 2018 to June 2019. Results: The most used treatment was surgery, chemotherapy, radiotherapy and hormonal therapy (24.8%). A binary regression analysis was performed with serial tumor marker levels, previously described. It was determined that having Ca 15.3 values greater than 25 U/ml 6 months after diagnosis increases the probability of developing metastases in the future (exp(B) 7,015) (p=<0.01). The same was demonstrated in the patients who also presented high concentrations of Ca 15.3 at 2 years after diagnosis, the probability of developing metastasis was present, although with a greater impact (exp (B) 27.67) (p=<0.00). Conclusions: It was determined that patients with high levels (greater than 25 U/ml), are more likely to develop metastases. This was demonstrated in those who presented high levels of the tumor marker within 6 months and 2 years after diagnosis, however in those patients who presented normal levels at the time of diagnosis and within the first 3 months, the probability was lower. Therefore, Ca 15.3 levels are a proven indicator to evaluate the evolution and prognosis in women with breast cancer.